ABSTRACT Impromidine (IMP) and arpromidine (ARP)-derived guanidines are more potent and efficacious guinea pig (gp) histamine H 2 -receptor (gpH 2 R) than human (h) H 2 R agonists and histamine H 1 -receptor (H 1 R) antagonists with preference for hH 1 R relative to gpH 1 R. We examined N G -acylated imidazolylpropylguanidines (AIPGs), which are less basic than guanidines, at hH 2 R, gpH 2 R, rat H 2 R (rH 2 R), hH 1 R, and gpH 1 R expressed in Sf9 cells as probes for ligand-specific receptor conformations. AIPGs were similarly potent H 2 R agonists as the corresponding guanidines IMP and ARP, respectively. Exchange of pyridyl in ARP against phenyl increased AIPG potency 10-fold, yielding the most potent agonists at the hH 2 R-G s␣ fusion protein and gpH 2 R-G s␣ identified so far. Some AIPGs were similarly potent and efficacious at hH 2 R-G s␣ and gpH 2 R-G s␣ . AIPGs stabilized the ternary complex in hH 2 R-G s␣ and gpH 2 R-G s␣ differently than the corresponding guanidines. Guanidines, AIPGs, and small H 2 R agonists exhibited distinct agonist properties at hH 2 R, gpH 2 R, and rH 2 R measuring adenylyl cyclase activity. In contrast to ARP and IMP, AIPGs were partial H 1 R agonists exhibiting higher efficacies at hH 1 R than at gpH 1 R. This is remarkable because, so far, all bulky H 1 R agonists exhibited higher efficacies at gpH 1 R than at hH 1 R. Collectively, our data suggest that AIPGs stabilize different active conformations in hH 2 R, gpH 2 R, and rH 2 R than guanidines and that, in contrast to guanidines, AIPGs are capable of stabilizing a partially active state of hH 1 R.
HIS exerts its biological effects through the H 1 R, H 2 R, H 3 R, and H 4 R, respectively (Hill et al., 1997; Hough, 2001) . We are particularly interested in the H 1 R and H 2 R (Klinker et al., 1996; Seifert et al., 2003; Dove et al., 2004) . The H 1 R couples to G q -proteins mediating phospholipase C activation, and the H 2 R couples to G s -proteins mediating AC activation (Hill et al., 1997) . In some systems, the H 2 R also couples to G q -proteins (Kü hn et al., 1996; Leopoldt et al., 1997) . We established expression systems for the H 1 R and H 2 R in Sf9 insect cells (Houston et al., 2002) . Sf9 cells can be cultured in large amounts and yield high GPCR expression levels. In Sf9 cell membranes, GPCR/G-protein coupling can be measured with high sensitivity using the steady-state GTPase activity. An advantage of the GTPase assay is that it assesses GPCR/ G-protein coupling at a proximal level, avoiding potential bias introduced by assessing more downstream events, such as effector activation or changes in gene expression. In the case of the H 1 R, coupling of the GPCR to insect cell G qproteins is determined using RGS proteins as signal enhancers for GTPase activity (Houston et al., 2002; Seifert et al., 2003) . In the case of the H 2 R, fusion proteins of GPCR and mammalian G s␣ -proteins are used Wenzel-Seifert et al., 2001) . GPCR-G s␣ fusion proteins ensure a defined 1:1 stoichiometry of the coupling partners and their efficient interaction (Seifert et al., 1999b) . By measuring GTP hydrolysis, potencies and efficacies of H 2 R agonists are assessed in an expression level-independent manner (Seifert et al., 1999b; Kelley et al., 2001; Wenzel-Seifert et al., 2001) . The H 2 R is differently glycosylated in mammalian and insect cells, but glycosylation does not affect the pharmacological GPCR properties (Fukushima et al., 1995; Houston et al., 2002) . Moreover, the pharmacological properties of H 1 Rs and H 2 Rs expressed in mammalian and insect cells are similar, rendering the latter system a useful model for extensive pharmacological studies (Kü hn et al., 1996; Beukers et al., 1997; Leopoldt et al., 1997; Kelley et al., 2001; Seifert et al., 2003) .
H 2 R agonists are divided into two classes. The first class comprises small molecules related to HIS (compound 1), most importantly AMT (compound 2), and DIM (compound 3) (Fig.  1) . The amino group of HIS forms an ionic interaction with Asp-98 in TM3, and the imidazole ring interacts with Tyr-182 and Asp-186 in TM5 (Gantz et al., 1992; Nederkoorn et al., 1994) . Small H 2 R agonists activate hH 2 R-G s␣S and gpH 2 R-G s␣S with similar potency and efficacy ). The second class of H 2 R agonists comprises long-chained and more bulky molecules, with IMP (compound 4) and ARP (compound 6) being the prototypes (Durant et al., 1978; Buschauer, 1989) . The guanidino group and the imidazolylpropyl moieties of IMP and ARP form similar interactions with H 2 Rs as the amino group and imidazole groups of HIS, respectively ). In addition, the 2-(5-methylimidazol-4-ylmethylthio)ethyl moiety of IMP and the 3-(4-fluorophenyl)-3-pyridylpropyl substituents of ARP interact with a pocket formed by multiple residues in TM3, 6, and 7 . At gpH 2 R-G s␣S , IMP and ARP are full agonists and are 30-and 16-fold more potent, respectively, than HIS. At hH 2 R-G s␣S , IMP and ARP are only partial agonists and are just 6-fold more potent than HIS . Modeling and mutagenesis studies revealed that the pharmacological differences between hH 2 R and gpH 2 R are attributable to the nonconserved Asp-271 in TM7 of gpH 2 R (Ala-271 in hH 2 Rs) and Tyr-17 in TM1 of gpH 2 R (Cys-17 in hH 2 R). Furthermore, the comparison of agonist efficacies in the GTPase assay with the efficacies of agonists at stabilizing the high-affinity ternary complex of the H 2 R with nucleotide-free G s␣ indicated that guanidines stabilize ligand-specific H 2 R conformations . Finally, ARP-derived compounds are H 1 R antagonists with a preference for gpH 1 R relative to hH 1 R, with Asn-84 in TM2 playing a crucial role in determining species selectivity of H 1 R ligands (Seifert et al., 2003; Bruysters et al., 2005) .
The aim of this study was to further probe the concept of ligand-specific H 1 R and H 2 R conformations. Therefore, we analyzed the interactions of H 1 R and H 2 R species isoforms with N G -acylated imidazolylpropylguanidines (AIPGs), which are less basic than guanidines (Ghorai, 2005) . UR-PG146 (compound 5) is the AIPG analog of IMP (compound 4), and UR-PG136 (compound 7) is the AIPG analog of ARP (compound 6). In AIPGs 8 through 16, various substituents were introduced at the imidazolylpropyl moiety, and compound 17 represents an imidazolylethyl analog, the shorter homolog, of UR-PG80 (compound 11).
Materials and Methods
Materials. Construction of baculoviruses encoding hH 2 R-G s␣S , gpH 2 R-G s␣S , hH 1 R, and gpH 1 R was described previously Seifert et al., 2003) . Baculoviruses encoding RGS proteins 4 and 19 were a gift from Dr. E. Ross (Department of Pharmacology, University of Southwestern Medical Center, Dallas, TX). Baculovirus encoding rH 2 R was a gift from Dr. C. Harteneck (Department of Pharmacology, Free University of Berlin, Berlin, Germany). Guanidines 4 and 6 were synthesized as described previously (Durant et al., 1978; Buschauer, 1989) . AIPGs 5 and 7 through 17 were prepared as described previously (Ghorai, 2005) . Structures of synthesized compounds were confirmed by 1 H nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry. Purity of compounds was Ͼ98% as determined by high-performance liquid chromatography or capillary electrophoresis (Schuster et al., 1997) . AIPGs 5 and 7 through 17 were prepared as trifluoroacetate salts to ensure water solubility. Stock solutions of compounds 1 through 17 (0.1, 1, and 10 mM) each were prepared in distilled water and stored at Ϫ20°C. Under these conditions, compounds were stable for at least 2 years (longer periods of time were not studied). Further dilutions of compounds 1 through 17 were prepared fresh daily. Sources of other materials are described elsewhere Houston et al., 2002; Seifert et al., 2003) . Baculovirus infection and culture of Sf9 cells and membrane preparation were performed as described previously ). H 2 R-G s␣ expression levels were 5 to 6 pmol/mg as assessed by immunoblotting using the M1 monoclonal antibody and ␤ 2 -adrenoceptor expressed at defined levels as stan- dard . H 1 R expression levels were 4 to 6 pmol/mg as assessed by [ 3 H]mepyramine saturation binding (Seifert et al., 2003) .
Steady-State GTPase Activity Assay. GTP hydrolysis in Sf9 membranes expressing H 2 R-G s␣ fusion proteins or H 1 R isoforms plus RGS proteins was determined as described previously Seifert et al., 2003) . In brief, assay tubes (100 l) contained Sf9 membranes (10 g of protein per tube), various ligands, 1.0 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 g of creatine kinase, and 0.2% (w/v) bovine serum albumin in 50 mM Tris/HCl, pH 7.4, and [␥-32 P]GTP (0.2-0.5 Ci/tube). Reactions were conducted for 20 min at 25°C and terminated by the addition of 900 l of slurry consisting of 5% (w/v) activated charcoal and 50 mM NaH 2 PO 4 , pH 2.0.
32 P i in supernatant fluids of reaction mixtures was determined by liquid scintillation counting.
AC Assay. AC activity in Sf9 membranes expressing nonfused hH 2 R, gpH 2 R, and rH 2 R was determined as described previously (Houston et al., 2002) . In brief, assay tubes (50 l) contained Sf9 membranes (50 -100 g of protein per tube), various ligands, 5.0 mM MgCl 2 , 0.4 mM EDTA, 40 M ATP, [␣- 32 P]ATP (1.0 -1.5 Ci/tube), 100 M GTP, 100 M cAMP, and an ATP-regenerating system consisting of phosphoenolpyruvate, pyruvate kinase, and myokinase in 30 mM Tris/HCl, pH 7.4. Reactions were conducted for 20 min at 37°C and terminated by the addition of 20 l of 2.2 N HCl.
[␣-
32 P]ATP was separated from [ 32 P]cAMP by column chromatography as described previously (Liu et al., 2001) , and [ 32 P]cAMP was determined by liquid scintillation counting.
Radioligand Binding Assays.
[ 3 H]Tiotidine competition binding experiments with Sf9 membranes expressing hH 2 R-G s␣S or gpH 2 R-G s␣S were performed as described previously . In brief, assay tubes (250 l) contained membranes (200 -250 g of protein per tube), 10 nM [ 3 H]tiotidine, and unlabeled ligands in binding buffer (12.5 mM MgCl 2 , 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). [
3 H]Mepyramine competition binding experiments with Sf9 membranes expressing hH 1 R or gpH 1 R plus RGS proteins were performed as described previously (Seifert et al., 2003) . In brief, assay tubes (500 l) contained membranes (20 -25 g of protein per tube), 2 nM [ 3 H]mepyramine, and unlabeled ligands in binding buffer. Bound radioligand was separated from free radioligand by filtration through GF/C filters, and filter-bound radioactivity was determined by liquid scintillation counting.
Miscellaneous. Protein concentrations were determined using the Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). All analyses of experimental data were performed with Prism 4.02 software (GraphPad-Prism, San Diego, CA). K i and K B values were calculated using the Cheng and Prusoff (1973) equation. Statistical comparisons in Table 1 were performed with the t test; statistical comparisons in Table 2 were performed with analysis of variance.
Results

Agonist Potencies and Efficacies of Guanidines and
AIPGs at hH 2 R-G s␣S and gpH 2 R-G s␣S in the GTPase Assay. All AIPGs studied, with the exception of compound 12 at hH 2 R, exhibited agonistic activity at H 2 R isoforms (Table  1) . At hH 2 R-G s␣S , exchange of the methylene group against a carbonyl group had little effect on the potency and efficacy of the couple 4 and 5 and moderately reduced potency but not efficacy in the couple 6 and 7. Omission of the p-fluoro substituent of the phenyl group in AIPGs (7 3 8) had little effect on potency and efficacy. The same was true for the exchange of the pyridyl group against an imidazolyl group (8 3 9). Substitution of the imidazolyl ring with an additional benzyl group (9 3 10) substantially reduced efficacy at hH 2 R. Most prominently, exchange of the pyridyl group against a phenyl group (8 3 11) increased potency by almost 10-fold, whereas efficacy was slightly reduced. Shortening of the linker between the carbonyl group and the phenyl rings was deleterious for agonist efficacy (11 3 12), whereas introduction of p-fluoro substituents at both phenyl rings (11 3 15, UR-PG55B) resulted in the most potent hH 2 R agonist known so far (25-fold more potent than HIS). Changes of the fluoro substitution pattern (compare 15 with 13 and 14) and exchange of one phenyl ring by a thiazole ring (compare 14 and 16) reduced agonist potency. Exchange of the imidazolylpropyl group against an imidazolylethyl group (11 3 17) TABLE 1 Agonist potencies and efficacies of HIS, guanidines, and AIPGs at hH 2 R-G s␣S and gpH 2 R-G s␣S in the GTPase assay Steady-state GTPase activity in Sf9 membranes expressing hH 2 R-G s␣S and gpH 2 R-G s␣S was determined as described under Materials and Methods. Reaction mixtures contained ligands at concentrations from 1 nM to 100 M as appropriate to generate saturated concentration-response curves. Data were analyzed by nonlinear regression and were best fit to sigmoid concentration-response curves. Typical basal GTPase activities ranged between ϳ1 and 2 pmol/mg/min, and the maximal stimulatory effect of histamine (100 M) amounted to 250 to 350% above basal. The efficacy (E max ) of histamine was determined by nonlinear regression and was set at 1.00. The E max values of other agonists were referred to this value. Data shown are the means Ϯ S.D. of five to eight experiments each performed in duplicate. The relative potency of histamine was set at 100, and the potencies of other agonists were referred to this value. We also calculated the ratio of the EC 50 values of H 2 R agonists for hH 2 R-G s␣S and gpH 2 R-G s␣S . 
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at ASPET Journals on May 9, 2017 jpet.aspetjournals.org strongly reduced efficacy at hH 2 R, whereas it reduced potency only moderately. Potencies and efficacies of AIPGs were higher at gpH 2 R-G s␣S than at hH 2 R-G s␣S (Table 1 ). These differences in interaction of AIPGs with hH 2 R and gpH 2 R resulted in correlations of efficacies ( Fig. 2A) and potencies (Fig. 2B ) that were shifted toward gpH 2 R. A shift toward higher potencies and efficacies at gpH 2 R relative to hH 2 R was also observed for guanidines . However, compared with the data obtained with guanidines, more AIPGs deviated from the correlation between gpH 2 R and hH 2 R. Most notably, AIPG 10 was more efficacious at hH 2 R than at gpH 2 R, and compound 17 was a similarly potent partial agonist at hH 2 R and gpH 2 R. AIPGs 10 and 15 were also just 2-fold more potent agonists at gpH 2 R-G s␣S than at hH 2 R-G s␣S .
Agonist Potencies and Efficacies of Small H 2 R Agonists, Guanidines, and UR-PG61 at hH 2 R, gpH 2 R, and rH 2 R in the AC Assay. Although the measurement of steady-state GTP hydrolysis at H 2 R-G s␣ fusion proteins provides a sensitive readout for agonist potencies and efficacies independently of the effector AC, fusion proteins do not represent a physiological system (Seifert et al., 1999b) . Therefore, we also determined the potencies and efficacies of representative H 2 R agonists at nonfused H 2 R isoforms by measuring AC activity (Table 2) . At hH 2 R, DIM (compound 3) was a 5-fold less potent agonist than HIS (compound 1), whereas AMT (compound 2) was 2-fold more potent than HIS. The guanidines IMP and ARP as well as a representative AIPG (UR-PG61, compound 14) were 4-to 6-fold more potent agonists than HIS. The efficacies of compounds 2 through 4, 6, and 14 at nonfused hH 2 R and hH 2 R-G s␣S were similar (Tables 1 and 2 ) ).
Whereas at hH 2 R-G s␣S and gpH 2 R-G s␣S , HIS is a similarly potent agonist (Table 1) , HIS was 6-fold less potent at nonfused gpH 2 R than at hH 2 R (Table 2) . A similar potency difference was observed between hH 2 R and rH 2 R. Therefore, agonist potencies among the three receptor systems could only be compared on the basis of relative agonist potencies, HIS being the reference for each H 2 R isoform. At gpH 2 R, DIM was similarly potent as HIS, whereas AMT was an almost 6-fold more potent agonist than HIS. ARP, IMP, and UR-PG61 were up to 170-fold more potent gpH 2 R agonists than HIS. In terms of efficacy, the compounds studied were all strong partial agonists, with DIM being the least efficacious agonist. In contrast, at gpH 2 R-G s␣S , DIM is a full agonist .
At rH 2 R, DIM was 2-fold less potent than HIS, whereas AMT was 6-fold more potent than HIS. IMP and ARP were up to 19-fold more potent agonists than HIS, and UR-PG61 was the most potent agonist among the compounds studied, surpassing the potency of HIS by 67-fold. At rH 2 R, ARP was almost a full agonist; compounds 2 through 4 were strong partial agonists, and compound 14 exhibited only moderate efficacy.
Ternary Complex Formation at hH 2 R-G s␣S and gpH 2 R-G s␣S . Agonists stabilize a high-affinity ternary complex with GPCR and the guanine nucleotide-free G-protein (De Lean et al., 1980; Seifert et al., 1998 Seifert et al., , 1999b . In many systems, stable GTP analogs, such as GTP␥S, disrupt the ternary complex and thereby reduce the agonist affinity of GPCR (De Lean et al., 1980; Seifert et al., 1998 Seifert et al., , 1999b . Interestingly, various guanidines differentially stabilize the ternary complex at hH 2 R-G s␣S and gpH 2 R-G s␣S , pointing to the existence of agonist-specific H 2 R conformations . Figure 3 shows the agonist competition curves of UR-PG146 (compound 5) and UR-PG136 (compound 7) on TABLE 2 Agonist potencies and efficacies of small H 2 R agonists, guanidines, and UR-PG61 at hH 2 R, gpH 2 R, and rH 2 R in the AC assay AC activity in Sf9 membranes expressing nonfused hH 2 R, gpH 2 R, or rH 2 R was determined as described under Materials and Methods. Reaction mixtures contained ligands at concentrations from 1 nM to 1 mM as appropriate to generate saturated concentration/response curves. Data were analyzed by nonlinear regression and were best fit to sigmoid concentration-response curves. Typical basal and maximal HIS-stimulated AC activities were as follows: hH 2 R, 1.5 and 5.0 pmol/mg/min, respectively; gpH 2 R, 1.5 and 5.0 pmol/mg/min, respectively; and rH 2 R, 0.7 and 3.0 pmol/mg/min, respectively. The efficacy (E max ) of histamine was determined by nonlinear regression and was set 1.00. [ 3 H]tiotidine (antagonist) binding to hH 2 R-G s␣S and gpH 2 R-G s␣S in the absence and presence of GTP␥S. Table 3 shows a summary of the binding properties of compounds 5 and 7 as well as the corresponding guanidines IMP (compound 4) and ARP (compound 6). UR-PG146 did not measurably stabilize the ternary complex in hH 2 R-G s␣S , as indicated by the missing rightward shift of the agonist competition curve in the presence of GTP␥S. In contrast, GTP␥S shifted the IMP competition curve at hH 2 R-G s␣S 4-fold to the right. Compared with hH 2 R-G s␣S , UR-PG146 was much more efficient at stabilizing the ternary complex at gpH 2 R-G s␣S , as indicated by the high fraction of high-affinity binding sites in the absence of GTP␥S and the strong rightward shift of the agonist competition curve by GTP␥S. UR-PG146 stabilized the ternary complex at gpH 2 R-G s␣S more efficiently than IMP.
In contrast to UR-PG146, UR-PG136 efficiently stabilized the ternary complex at hH 2 R-G s␣S , as indicated by the strong rightward shift of the agonist competition curve by GTP␥S. ARP also stabilized the ternary complex at hH 2 R-G s␣S , but unlike with UR-PG136, distinct high-affinity binding sites were discriminated with ARP. UR-PG136 stabilized the ternary complex in gpH 2 R-G s␣S less efficiently than in hH 2 R-G s␣S , as evident from the smaller shift of the agonist competition curve by GTP␥S. At gpH 2 R-G s␣S , ARP was an efficient stabilizer of the ternary complex, but this ternary complex formation was insensitive to guanine nucleotides, as seen from the preservation of distinct high-affinity binding sites in the presence of GTP␥S.
Interaction of Guanidines and AIPGs with the H 1 R. Because guanidines are H 1 R antagonists with up to 10-fold selectivity for the gpH 1 R relative to the hH 1 R (Seifert et al., 2003) , we also examined the interactions of AIPGs with H 1 Rs. Compared with the agonist HIS, the antagonist ARP exhibited 6-fold higher affinity to hH 1 R in [ 3 H]mepyramine competition binding experiments, and the affinity of ARP to gpH 1 R was 150-fold higher (Table 4) . IMP exhibited selectivity for the gpH 1 R relative to the hH 1 R as well. Strikingly, the exchange of a methylene group against a carbonyl group (4 3 5 and 6 3 7) reduced the affinity of AIPGs for H 1 R up to ϳ300-fold. In general, AIPGs exhibited higher affinity for gpH 1 R than for hH 1 R, but the gpH 1 R selectivity for AIPGs was less pronounced than for guanidines (4 3 5 and 6 3 7). In addition, in the case of UR-PG131A (compound 9) and UR-PG55B (compound 15), affinity for both H 1 R isoforms was similar.
To answer the question whether AIPGs are H 1 R agonists or antagonists, we examined the effects of the compounds on GTPase activity (Table 5) . AIPGs exhibited weak to moderate 
TABLE 3
Agonist binding properties of guanidines and AIPGs at hH 2 R-G s␣S and gpH 2 R-G s␣S Agonist competition binding was determined as described under Materials and Methods. Data shown in Fig. 3 were analyzed by nonlinear regression for best fit to monophasic or biphasic competition curves. Data shown are the means of five to seven experiments performed in duplicate. Numbers in parentheses represent the 95% confidence intervals. K h and K l designate the dissociation constants for the high-and low-affinity state of H 2 R, respectively. %R h indicates the percentage of high-affinity binding sites. The corresponding values in the presence of GTP␥S (10 M) are referred to as K hGTP␥S , K lGTP␥S , and %R hGTP␥S , respectively. If data were best fit to monophasic curves, data are listed under K l and K lGTP␥S , respectively.
partial agonistic activity at hH 1 R, with UR-PG126 (compound 16) being the most efficacious compound. AIPGs were 10-to 70-fold less potent than HIS at hH 1 R. At gpH 1 R, AIPGs were considerably less efficacious partial agonists than at hH 1 R, rendering calculation of agonist potencies impossible. For those compounds, antagonist potencies were calculated. The GTPase antagonist studies corroborated the notion that AIPGs exhibit only low affinity for hH 1 R and gpH 1 R with K B values in the 2 to 15 M range. Of note, in the functional antagonist assay, AIPG 11 exhibited 2-fold higher affinity for hH 1 R than for gpH 1 R.
Discussion
Previous studies with HL-60 promyelocytes and H 2 R-G s␣ fusion proteins provided the first evidence for the notion that H 2 R agonists stabilize distinct ligand-specific H 2 R conformations, i.e., multiple active H 2 R states (Gespach et al., 1982; Seifert et al., 1992; Kelley et al., 2001; Wenzel-Seifert et al., 2001) . A multiple-state model is a fundamental concept because it implies more versatile manipulation of GPCR-mediated signaling than within a two-state model assuming a single inactive (R) and a single active (R*) state Kenakin, 2003) . An increasing number of reports indicate that ligand-specific active states are a general property of GPCRs encompassing adrenoceptors, dopamine receptors, serotonin receptors, and cannabinoid receptors (Seifert et al., 1999a Villazon et al., 2003; Gay et al., 2004; Clarke, 2005; Mukhopadhyay and Howlett, 2005) . With respect to the H 1 R and H 2 R, ARP-derived guanidines are particularly useful conformational probes because these ligands discriminate between species isoforms of those GPCRs Wenzel-Seifert et al., 2001; Seifert et al., 2003) . These data prompted us to examine a series of ARP-derived compounds in which the N G -alkyl substituent was replaced against an N G -alkanoyl group (compare compounds 4 and 6 versus 5 and 7 through 17) (Fig. 1) . The resulting AIPGs are less basic than the corresponding guanidines. According to a two-state model, a change in basicity would be expected to result in quantitative changes in interactions of compounds with GPCRs, whereas within the framework of a multiple-state model, qualitative changes would be expected to occur.
The AIPG UR-PG55B (compound 15) is the most potent hH 2 R agonist known so far, surpassing the potency of ARP, the prototypical guanidine, by almost 4-fold (Table 1) . How- , 2 nM ͓ 3 H͔mepyramine, and unlabeled ligands at concentrations of 10 nM to 1 mM as appropriate to generate saturated competition curves. Data were analyzed by nonlinear regression and were best fit to one-site (monophasic) competition curves. Data shown are the means Ϯ S.D. of three to five experiments performed in duplicate. The relative affinity of HIS was set to 100, and the affinities of other ligands were referred to this value. We also calculated the ratio of the K B values for hH 1 R and gpH 1 R (gp/h). ever, at gpH 2 R-G s␣ , UR-PG80 (compound 11) rather than compound 15 is the most potent gpH 2 R agonist. Whereas ARP-derived guanidines exhibit similar affinity for the couples hH 1 R/hH 2 R and gpH 1 R/gpH 2 R Seifert et al., 2003) , AIPGs exhibit up to 1000-fold selectivity for H 2 Rs relative to Hs 1 Rs (Tables 1, 4 , and 5). These differences between AIPGs and guanidines were the first indication for distinct interactions of AIPGs with H 1 R and H 2 R.
Ionic interaction of the amino group of HIS and the guanidino group of IMP, ARP, and related compounds with Asp-98 in TM3 is important for high-affinity ligand-H 2 R interaction (Gantz et al., 1992; Kelley et al., 2001) . Regardless of the reduced pK a values (in the range of 7-8 for AIPGs compared with ϳ12.5 for guanidines), the compounds are sufficiently basic to form an ionic interaction or charge-assisted hydrogen bond of the N G -acylguanidino group with Asp-98 at physiological pH. The geometry of both series of compounds, N G -alkylguanidines and N G -acylguanidines, is sufficiently similar to assume comparable binding modes to H 2 Rs (Fig. 1) . Surprisingly, certain AIPGs even surpass guanidines in terms of agonistic potency at H 2 R isoforms from various species (Tables 1 and 2 ). With respect to AIPG substitution, the most striking result is that the exchange of the pyridyl group against a second phenyl group (8 3 11) increased agonist potency up to 10-fold ( Fig. 1; Table 1 ). For hH 2 R, the increase in affinity of AIPGs by the diphenyl substitution was expected because Ala-271 in TM7 facilitates hydrophobic interactions ). However, in gpH 2 R, the pyridyl group of ARP participates in ion dipole interactions with Asp-271, which cannot take place with a phenyl ring . These data are explained by a model in which AIPG 11 adopts a different orientation in gpH 2 R than in guanidines, allowing it to interact with hydrophobic amino acids present in TM3, 6, and 7.
Although, in general, AIPGs are more potent and efficacious at gpH 2 R than at hH 2 R (Fig. 2) , we observed some exceptions from this rule. Notably, the hH 2 R tolerates introduction of an additional benzyl group at the imidazolyl group better in terms of efficacy than the gpH 2 R (9 3 10) ( Fig. 1 ; Table 1 ). In addition, the hH 2 R tolerates an imidazolylethyl group better concerning agonist potency than the gpH 2 R (11 3 17). Moreover, AIPGs 10 and 15 are similarly potent agonists at hH 2 R and gpH 2 R. The potency-enhancing effect of the second phenyl ring in both hH 2 R and gpH 2 R (8 3 11) and the distinct structure-activity relationships of AIPGs at hH 2 R and gpH 2 R (9 3 10 and 11 3 17, 10, and 15) in the GTPase assay prompted us to examine ternary complex formation because this parameter is sensitive at unmasking ligand-specific GPCR conformations Seifert et al., 2001) . Indeed, although the couples IMP (compound 4)/UR-PG146 (compound 5) and ARP (compound 6)/ UR-PG136 (compound 7) resemble each other with respect to efficacy in the GTPase assay (Table 1) , the compounds differ substantially from each other regarding ternary complex formation ( Fig. 3; Table 3 ). At gpH 2 R-G s␣S , UR-PG146 was particularly efficient at ternary complex formation. Efficient ternary complex formation that is not accompanied by a correspondingly high efficacy in terms of steady-state GTP turnover is indicative of the formation of nonsignaling (frozen) ternary complexes Kenakin, 2003) . The existence of ligand-specific H 2 R conformations stabilized by AIPGs is further supported by the fact that, at hH 2 R, the differences between the two classes of compounds. These data indicate that guanidines and AIPGs also stabilize distinct H 1 R conformations. It is particularly noteworthy that AIPGs exhibit higher efficacies at hH 1 R than at gpH 1 R (Table 5). Moreover, some AIPGs exhibit similar (compounds 9 and 15) or higher affinity (compound 11) for hH 1 R relative to gpH 1 R (Tables 4 and 5 ). All bulky agonists studied so far exhibited a preference for gpH 1 R relative to hH 1 R in terms of affinity and/or efficacy (Seifert et al., 2003) .
In conclusion, AIPGs stabilize different active conformations in hH 2 R, gpH 2 R, and rH 2 R than guanidines. Moreover, AIPGs are more efficient at stabilizing a partially active state in hH 1 R than in gpH 1 R. Our data corroborate the concept that a multiple-state model is more appropriate to describe ligand/GPCR interactions than a two-state model.
